<DOC>
	<DOCNO>NCT00609492</DOCNO>
	<brief_summary>The purpose study evaluate safety , reactogenicity immunogenicity booster dose GlaxoSmithKline ( GSK ) Biologicals´ pneumococcal conjugate vaccine co-administered booster dose DTPa-IPV/Hib ( Infanrix-IPV/Hib ) preterm born child age 16-18 month . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number =NCT00390910 ) . Subjects participate study receive three dos pneumococcal vaccine primary study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Evaluate Safety Immunogenicity Booster Dose Pneumococcal Conjugate Vaccine Preterm Born Infants .</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrol study . A male female , include , 1618 month age time booster vaccination . A male female previously participate study 107737 receive three dos pneumococcal conjugate vaccine . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Concurrently participate another clinical study , time study period ( active phase extend safety followup ) , subject expose investigational noninvestigational product . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede booster dose study vaccine , plan use study period ( active phase 5 month extend safety followup ) . Chronic administration immunosuppressant immunemodifying drug within 6 month prior booster dose study vaccine . Planned administration/administration vaccine foreseen study protocol , period start one month ( 30 day ) booster dose study vaccine ( Visit 1 ) followup visit ( Visit 2 ) . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b and/or Streptococcus pneumoniae study vaccine study 107737 History intercurrent diphtheria , tetanus , hepatitis B , pertussis , polio , Haemophilus influenzae type b disease . History allergic disease reaction likely exacerbate component vaccine . History seizures progressive neurological disease Acute disease time enrolment . Febrile illness define oral , axillary tympanic temperature &lt; 37.5°C / rectal temperature &lt; 38°C . A temperature great equal cutoff warrant deferral vaccination pending recovery subject . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins , exception monoclonal antibody RSV , and/or blood product within three month precede booster dose study vaccine plan administration active phase study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>